1. Market Research
  2. > Healthcare
  3. > Medical Facility Market Trends
  4. > CRO Quality Benchmarking - Phase I Service Providers (2013)

CRO Quality Benchmarking - Phase I Service Providers (2013)

  • December 2013
  • -
  • Industry Standard Research
  • -
  • 132 pages

In its 5th year, ISR’s “CRO Quality Benchmarking” series provides the pharmaceutical idustry with a unique resource to evaluate and select CROs, while offering clinical service providers valuable insight into their service quality, their competitors’ service quality, and their customers’ outsourcing behaviors. This year, ISR’s 2013 Phase I benchmarking report includes data from 360 unique service evaluations across 22 Phase I service providers.

Table Of Contents

CRO Quality Benchmarking - Phase I Service Providers (2013)
Copyright and Usage Guidelines 6
Introduction 7
Methodology 8
Respondent Demographics 9
Participant Years of Industry Experience 9
Participant Geography 9
Number of Ratings per Company 10
Major sections 11
Outsourcing Behaviors, Attitudes, Beliefs, and Intentions 13
Phase I Leaders, unprompted 14
Phase I Leaders, Prompted 15
Received Proposals 16
Service Provider Usage 17
Service Provider Cost Perceptions 18
Service Provider Selection Drivers 20
Most Important Service Provider Attributes 21
Service Provider Attributes Gaining Importance 22
Service Provider Performance and Scorecards across Attributes 23
Figure 1 - “Staff Characteristics” Ratings 25
Figure 2 - “Operational Excellence” Ratings 26
Figure 3 - “Organizational and Finance” Ratings 27
Performance Summary by Category 28
Outcome Measures: EPIâ„¢ and Customer Loyalty 29
Summary of EPIâ„¢ 30 Service Provider Loyalty - A compilation of Overall Satisfaction, Willingness to Recommend, and Likelihood to Use Again 31
Company Service Quality Profiles 32
Celerion 34
Charles River 35
Covance 36
ICON 37
InVentiv Health Clinical 38
Medpace 39
PAREXEL 40
PPD 41
PRA 42
PRACS Institute 43
Quintiles 44
WCCT 45
Study Data 46
Phase I 47
Phase I Leaders, unprompted 47
Phase I Leaders, Prompted 48
Received Proposals 49
Most Important Service Provider Attributes 50
Service Provider Attributes Gaining Importance 51
Service Provider Usage 52
Service Provider Preference 53
Best Service Provider at Differentiation 54
Service Provider Cost Experience 55
Service Provider Cost Experience by users of past 18 months 56
Summary of EPIâ„¢ 57
Service Provider Loyalty 58
Service Provider Loyalty - A compilation of Overall Satisfaction, Willingness to Recommend, and Likelihood to Use Again 58
Overall Satisfaction with Service Providers 59
Willingness to Recommend Service Providers 60
Likelihood to Use Service Providers Again 61
Service Providers Drill-downs 62
CEDRA 63
Celerion 64
Charles River 66
Chiltern 68
Covance 70
DaVita 72
DCRI-Duke 74
ICON 76
INC Research 78
InVentiv Health Clinical 80
Medpace 82
PAREXEL 84
PPD 86
PRA 88
PRACS Institute 90
Premier Research 92
Quintiles 94
Rho 96
SGS Life Sciences 98
Siro Clinpharm 100
Theorem 102
US Oncology 104
WCCT 106
Cross-service provider performance 108
Access to “unique” tests, machines, equipment 108
Access to a broad range of services beyond clinic / volunteer management…109
Access to patient populations 109
Data quality 110
Experience of the Phase I unit's lead investigator 110
Financial strength/ stability 111
Local market / Regulatory knowledge 111
Location of Phase I unit(s) in different global region 112
Location of Phase I unit(s) within your country 112
Low cost 113
Meeting database lock timelines 113
Meeting first patient / first visit timelines 114
Meeting overall project timelines 114
Minimizing change orders 115
Minimizing staff turnover 115
Offered innovative solutions 116
Overall value 116
Patient/ volunteer recruitment 117
Positive experience with service provider 117
Project manager quality 118
Project team chemistry 118
Scientific knowledge 119
Speed of site / Investigator recruitment 119
Speed of site start-up 120
Technology for real-time access to data 120
Therapeutic expertise 121
Timely access to open bed / clinic space 121
Timely project communications 122
Up-front contingency planning, risk management 122
Trade-Offs 123
Respondent Demographics 125
Company Type 125
Primary Area of Responsibility 126
Outsourcing Responsibility 127
Job Title 127
Recent Activity in Outsourced Activities 128
Phase Responsibility 128
Involvement in Clinical Development Process 129
Years in the Industry 130
Location 130
Therapeutic Area 131
About Industry Standard Research 132

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Global Tumor Marker Diagnostic Testing Market: Future Horizons and Growth Strategies--Instrument and Reagents Supplier Shares, Country Segment Forecasts, Competitive Intelligence, Opportunities

Global Tumor Marker Diagnostic Testing Market: Future Horizons and Growth Strategies--Instrument and Reagents Supplier Shares, Country Segment Forecasts, Competitive Intelligence, Opportunities

  • $ 21100
  • Industry report
  • August 2016
  • by Venture Planning Group

Complete report $34,750.  DataPack (test volumes, sales forecasts, supplier shares) $21,100. Highlights - Identifies and evaluates major business opportunities emerging in the tumor marker market during ...

2016 Competing in the Global Cancer Diagnostics Market

2016 Competing in the Global Cancer Diagnostics Market

  • $ 21100
  • Industry report
  • October 2016
  • by Venture Planning Group

This new VPGMarketResearch.com comprehensive seven-country study identifies and evaluates major business opportunities emerging in the cancer diagnostics market during the next five years; examines trends ...

Tumor Markers 2020: Reagents and Instrumentation--Supplier Shares and Strategies, Country Segment Forecasts, Emerging Opportunities

Tumor Markers 2020: Reagents and Instrumentation--Supplier Shares and Strategies, Country Segment Forecasts, Emerging Opportunities

  • $ 21100
  • Industry report
  • October 2016
  • by Venture Planning Group

Complete report $34,750.  DataPack (test volumes, sales forecasts, supplier shares) $21,100. Highlights - Identifies and evaluates major business opportunities emerging in the tumor marker market during ...


ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.